The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Universal Biosensors (UBI) has signed a distribution agreement with Vines to Vintages for the distribution of its wine-testing platform, Sentia, in Canada
  • Sentia analyses sulfur dioxide in post-fermentation red or white wine
  • The agreement is for three years and includes standard renewal and termination options
  • On the market, UBI is up 1.96 per cent and is trading at 52 cents per share

Universal Biosensors (UBI) has signed a distribution agreement with Vines to Vintages for the distribution of its wine-testing platform device, Sentia, in Canada.

Vines to Vintages is an independent wine laboratory performing analysis for wineries in Canada and United States. It also sells winemaking supplies and equipment.

Sentia analyses sulfur dioxide in post-fermentation red or white wine. The product is then able to display, through a touchscreen, the test results in under a minute.

Sulfur dioxide is added in the winemaking process to protect the wine from oxidation and bacterial spoilage.

The agreement is for three years and includes standard renewal and termination options.

UBI CEO John Sharman said this is another positive step in the commercialisation of Sentia globally.

“Vines to Vintages is well represented in all of Canada’s wine regions and has access to 700 wineries. The deal includes an initial commitment to purchase
Sentia devices and strips which will be delivered over the course of the next few weeks,” he said.

“We believe the possibility of Sentia’s future testing capability for Glucose,
Fructose, Malic Acid and others will add significant value to the winemaking industry,” he added.

UBI is currently negotiating terms with a number of key industry players around the world and looks forward to reporting additional distribution partnerships in the future.

On the market, UBI is up 1.96 per cent and is trading at 52 cents per share at 2:49 pm AEDT.

UBI by the numbers
More From The Market Online

PharmAust CEO’s sayanora triggers stock plunge

Clinical-stage biotechnology company, PharmAust shares plunged 24 per cent so this morning, following the resignation of…

Recce wins safety board approval to dose 4g in R327 UTI infusion trial

Recce Pharma will dose patients with 4g of its R327 intravenous solution to treat UTIs in…

Emyria locks in $2.3M to progress MDMA research – with Chair adding $0.3M

WA-based and ASX-listed Emyria is seeking to further research using MDMA to treat PTSD. The chair…

Genetic Signatures wins TGA greenlight for flu test device – just before winter

Genetic Signatures (ASX:GSS) shares were down -1.45% to 68cps on Monday, even as the company reported…